Proteinuria and the Progression of Chronic Renal Disease in the Dog
WSAVA 2002 Congress
Gregory F. Grauer, DVM, MS, Diplomate, ACVIM (Internal Medicine)
Department of Clinical Sciences, Kansas State University
Manhattan, Kansas, USA

Until relatively recently, canine glomerular disease was thought to be uncommon and unimportant. It is now recognized that glomerulonephritis (GN) is common in dogs and can lead to chronic renal insufficiency/failure.1 The magnitude of this problem is emphasized by studies that have shown the incidence of GN in randomly selected dogs to be as high as 43-90%.2,3 The majority of canine GN is mediated by immunopathogenic mechanisms associated with the presence of immune complexes in glomerular capillary walls. Circulating immune complexes may be deposited in the glomerulus or immune complex formation may occur in situ. The glomerulus provides a unique environment for injurious immune complexes to stimulate production of bioactive mediators like eicosanoids, cytokines, and growth factors. These substances may be produced by endogenous glomerular cells or by recruited platelets, macrophages, and neutrophils. In addition to production of these bioactive mediators, several factors including activation of the complement system, platelet aggregation, infiltration of neutrophils and macrophages, activation of the coagulation system, and fibrin deposition can contribute to glomerular damage associated with the presence of immune complexes. Histologically, the glomerulus responds to this injury by cellular proliferation, thickening of the capillary walls, and if the injury persists, hyalinization and sclerosis. Once a glomerulus has been irreversibly damaged, the entire nephron becomes nonfunctional and fibrous tissue replacement occurs. Chronic interstitial nephritis is frequently the histopathologic lesion observed in dogs with chronic renal failure, but this end-stage lesion can result from primary glomerular, tubular, or vascular lesions as well as interstitial tissue lesions.

Loss of plasma proteins into the urine is one of the earliest functional defects recognized in GN. Consequences of plasma protein loss may include sodium retention, hypercoagulability, muscle wasting, and weight loss. There does not appear to be a relationship between proteinuria and glomerular filtration rate in dogs with GN.4 Azotemia and renal insufficiency/failure occur as more and more nephrons are irreversibly damaged and become nonfunctional. Late in the disease process, proteinuria in total tends to diminish associated with the decreased number affected glomeruli. Plasma protein loss on an individual remaining nephron basis however, may remain significant. Indeed, individual nephron hyperfiltration and proteinuria have been documented in dogs with the remnant kidney model of renal failure.5

There is increasing evidence in laboratory animals and human beings that proteinuria can cause glomerular and tubular damage and result in progressive nephron loss. Plasma proteins that have crossed the glomerular capillary wall can accumulate within the glomerular tuft and stimulate mesangial cell proliferation and increased production of mesangial matrix inhuman beings.6 In addition, excessive amounts of protein in the glomerular filtrate can be toxic to human tubular epithelial cells and can lead to interstitial inflammation, fibrosis, and cell death.7 Proximal tubular cells normally reabsorb protein from the glomerular filtrate by endocytosis. Albumin and other proteins accumulate in lysosomes and are then degraded into amino acids and returned to the circulation. In proteinuric conditions, excessive lysosomal processing can result in swelling and rupture of lysosomes causing enzymatic damage to the cytoplasm in rat kidneys.8 Tubular injury may also occur in rats as a consequence of tubular obstruction with proteinaceous casts.9 Increased glomerular permeability to plasma proteins allows tubular contact with transferrin, complement, and lipoproteins in addition to albumin. Transferrin increases iron uptake by epithelial cells. Once inside the cell the iron ions catalyze the formation of reactive oxygen species that can cause peroxidative injury in rats.10 Complement proteins can be activated on the brush border of proximal tubular cells cultured from human beings resulting in insertion of a membrane attack complex followed by cytoskeletal damage and cytolysis.11 Reabsorbed lipoproteins can release lipid moieties that can accumulate into lipid droplets or be oxidized to toxic radicals.12 All of these processes can irreversibly damage the proximal tubule and result in nephron loss. Exposure to plasma proteins at the apical surface of cultured human tubular cell results in a basolateral release of growth factors, fibronectin, and monocyte chemoattractant protein-1.13 This process may also induce excessive tubular expression of tranforming growth factor-ß1 that can result in the interstitial inflammation and scarring typical of end-stage kidney disease.14 Osteoponin has been detected in protein congested proximal tubular cells from rats in 2 different models of renal disease.15 By virtue of its chemoattractant action, osteopontin is a likely mediator of a proximal tubule-dependent inflammatory pathway in response to an excessive protein load. Another mediator of tubulointerstitial damage related to excessive tubular cell protein reabsorption is the up-regulation of tubular-derived endothelin-1 (ET-1).16 Tubular ET-1 formed in response to increasing concentrations of albumin presented to the proximal tubular epithelium is secreted toward the basolateral cellular compartment and accumulates in the interstitium causing ischemia. Endothelin-1 also binds to receptors on interstitial fibroblasts and causes interstitial cellular proliferation and extracellular matrix production.16

Several studies in human patients with proteinuric renal disease suggest that proteinuria is linked to renal disease progression. In 176 patients with non-insulin dependent diabetes mellitus that were studied over 5 years, baseline albuminuria was a predictor for the development of incipient nephropathy.17 Similarly, in people with insulin-dependent diabetes mellitus and established diabetic nephropathy, higher levels of proteinuria at baseline predicted progression of the nephropathy over a median period of 3 years.18 In another study of people with chronic GN, the decrease in proteinuria via several different treatments predicted the change in the slope of the reciprocal of the serum creatinine over 6 months.19 Paired renal biopsies taken 5.8 years apart in people with insulin-dependent diabetes mellitus showed that mesangial expansion was linked to microalbuminuria and that tubulointerstitial changes occurred as a result of advanced glomerular injury.20 Finally, in a study of 7728 nondiabetic people, macroalbuminuria was independently associated with decreased glomerular filtration.21

Evidence linking proteinuria to progression of renal disease in dogs is less convincing. As stated earlier, individual nephron hyperfiltration and proteinuria have been documented in dogs with the remnant kidney model of renal failure.5 However, treatments that have slowed the functional decline and/or histologic changes associated with this model have had variable effects on proteinuria. Angiotensin converting enzyme inhibition and w-3 fatty acid supplementation have decreased proteinuria and slowed progression,22,23 however calcium blockade treatment resulted in increased mesangial cell proliferation despite decreasing proteinuria.22 Other treatments, such as reduction of dietary phosphorus, decreased renal disease progression in remnant kidney dogs but had no effect on proteinuria.24 In dogs with experimentally induced immune complex GN, treatment with a thromboxane synthetase inhibitor decreased proteinuria and attenuated the development of glomerular lesions but had no effect on established lesions.25,26 Finally, reduction of proteinuria via angiotensin converting enzyme inhibition treatment slowed progression of renal disease in dogs with 2 different types of naturally occurring glomerulopathies.27,28

In summary, a direct pathogenetic link between proteinuria and renal damage has not been established in the dog but the evidence is accumulating in other species. We need to increase our understanding of the effects of proteinuria on the glomerulus, the tubule, and the interstitium in the dog. It is possible that proteinuria may be much more than a diagnostic marker of glomerular disease.

References

1.  MacDougall DF, Cook T, Steward AP, et al. Canine chronic renal disease: Prevalence and types of glomerulonephritis in the dog. Kidney Int 1986; 29:1144-1151.

2.  Shirota K, Takahashi R, Fujiwara K, et al. Canine interstitial nephritis with special reference to glomerular lesions and filariasis. Jpn J Vet Sci 1979; 41:119-25.

3.  Muller-Peddinghaus R, Trautwein G. Spontaneous glomerulonephritis in dogs 1. Classification and immunopathology. Vet Pathol 1977; 14:1-13.

4.  Allen TA, Fettman MJ, Jaenke RS, Wilke WL. Renal functional relationships in dogs with glomerulopathies. Am J Vet Res 1987; 48:610-612.

5.  Brown SA, Finco DR, Crowell WA, et al. Single-nephron adaptation to partial renal ablation in the dog. Am J Physiol 1990; 258;F495-F503.

6.  Jerums G, Panagiotopoulos S, Tsalamandris C, et al. Why is proteinuria such an important risk factor for progression in clinical trials? Kidney Int 1997; 52:S87-S92.

7.  Tang S, Sheerin NS, Zhou W, et al. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 1999; 10:69-76.

8.  Olbricht CJ, Cannon JK, Garg LC, Tisher CC. Activities of cathepsin B and L in isolated nephron segments from proteinuric and nonproteinuric rats. Am J Physiol 1986; 250:F1055-1062.

9.  Bertani T, Cutillo F, Zoja C, et al. Tubulointerstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986; 30:488-496.

10. Alfrey AC, Froment DH, Hammond WS. Role of iron in tubulointerstitial injury in nephrotoxic serum nephritis. Kidney Int 1989; 36:753-759.

11. Camussi G. Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int 1994; 45:451-460

12. Ong A, Moorhead J. Tubular lipidosis: Epiphenomenon or pathgenetic lesion in human renal disease. Kidney Int 1994; 45:753-762.

13. Harris KP, Burton C, Walls J. Proteinuria: A mediator of interstitial fibrosis? Contrib Nephrol 1996; 118:173-179.

14. Remuzzi G. Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 1995; 4:339-342.

15. Abbate M, Zoja C, Corna D, et al. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signal of interstitial inflammation. J Am Soc Nephrol 1998; 9:1213-1224.

16. Benigni A, Zoja C, Remuzzi G. Biology of disease: The renal toxicity of sustained glomerular protein traffic. Lab Invest 1995; 73:461-468.

17. Gall MA, Hougaard P, Borchjohnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus-prospective, observational study. Brit Med J 1997; 314:783-788.

18. Breyer JA, Bain RP, Evans JK, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 1996; 50:1651-1658.

19. Gansevoort RT, Navis GJ, Wapstra FH, et al. Proteinuria and progression or renal disease: Therapeutic implications. Curr Opin Nephrol Hypertens 1997; 6:133-140.

20. Fioretto P, Steffes MW, Sutherland DER, Mauer M. Sequential renal biopsies in insulin-dependent diabetes patients: Structural factors associated with clinical progression. Kidney Int 1995; 48:1929-1935.

21. Pinto-Sietsma S, Janssen WMT, Hillege HL, et al. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 2000; 11:1882-1888.

22. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimes on renal hemodynamics and proteinuria. Kidney Int 1993; 43:1210-1218.

23. Brown SA, Brown CA, Crowell WA, et al. Beneficial effects of chronic administration of dietary w-3 polyunsaturated fatty acids in dogs with renal insufficiency. J Lab Clin Med 1998; 131:447-455.

24. Finco DR, Brown SA, Crowell WA, et al. Effects of phosphorus/calcium-restricted and phosphorus calcium-replete 32% protein diets in dogs with chronic renal failure. Am J Vet Res 1992; 53:157-163.

25. Longhofer SL, Frisbie DD, Johnson HC, Culham CA, Cooley JA, Schultz KT, Grauer GF. Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis. Am J Vet Res 52: 480-487, 1991.

26. Grauer GF, Frisbie DD, Longhofer SL, Cooley AJ. Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs. Am J Vet Res 53:808-813, 1992.

27. Grodecki KM, Gains MJ, Baumal R, et al. Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Path 1997;117:209-225.

28. Grauer GF, Greco DS, Getzy DM, et al. Effects of enalapril vs placebo as a treatment for canine idiopathic glomerulonephritis. J Vet Int Med 2000; 14:526-533.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Gregory F. Grauer, DVM, MS, Dipl. ACVIM (Internal Medicine)
Department of Clinical Sciences
Kansas State University
Manhattan, Kansas, USA


MAIN : : Proteinuria
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27